Login to Your Account

Novartis Paying $75M Up Front

Portola's Anticlotting Drug Gains Partner in Potential $575M Deal

By Jennifer Boggs

Friday, February 13, 2009
In its first major collaboration, privately held Portola Pharmaceuticals Inc. partnered one of its two lead antithrombotic programs with Novartis AG in a deal potentially worth up to $575 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription